Comparative analysis of azathioprine versus cyclosporine-based therapy in primary haplo-identical live-donor kidney transplantation : a 20-year experience

الملخص EN

Chronic allograft nephropathy (CAN) remains a major cause of graft failure over the long term, second only to patient mortality.

The main adverse effects of cyclosporine A (CsA) include nephrotoxicity, hypertension, symptomatic hyperuricemia, hirsutism, and gum hyperplasia.

Available studies among live related donor renal transplants lack adequate information regarding the long-term efficacy and safety of primary CsA-based immunosuppressive regimens.

This prospective randomized study is aimed at evaluating the long-term results of CsA-based immunosuppressive protocols in livedonor kidney transplantation.

The follow-up data of 444 renal transplant recipients operated at the Urology and Nephrology Center, Mansoura University, prior to 1996 were reviewed.

Primary immunosuppressive protocols included: steroids and azathioprine (group I, 130 cases); steroids and CsA (group II, 75 cases); and steroids, CsA, and azathioprine (group III, 239 cases).

Only adult primary renal transplant recipients with age ranging between 18 and 60 years and one haplotype HLA mismatch with the donor were included.

All patients received kidneys from living related donors with previous donor non-specific blood transfusions.

The percentage of cases with chronic rejection was significantly higher in group III.

Living cases with graft failure were significantly higher in group III, whereas mortality was significantly higher in group I.

Diabetic patients and those with serious bacterial infections were significantly more prevalent in group II.

Hypertensive patients were significantly more common in groups I and II.

Liver disease was more prevalent among patients in group III.

Our study suggests that the long-term results of treatment with steroids and azathioprine are satisfactory in live related donor kidney transplant recipients.

Chronic rejection was significantly higher in patients in group III, possibly due to the risk of CsA nephrotoxicity.

Groups with CsA-based protocols experienced many adverse reactions of CsA such as hypertension, diabetes mellitus, and chronic rejection.